Table 4.
Demographic and clinical characteristics, by seroreversion status.
| Non-seroreversion (n = 235) | Seroreversion (n = 71) | P value | ||
|---|---|---|---|---|
| Age (years) | < 45 years | 112 (71.8%) | 44 (28.2%) | 0.045 |
| ≥45 years | 123 (82.0%) | 27 (18.0%) | ||
| Sex | Female | 161 (75.2%) | 53 (24.8%) | 0.4 |
| Male | 74 (80.4%) | 18 (19.6%) | ||
| Baseline IgG anti-SARS-CoV-2 Antibody Titer | T1 | 49 (48.0%) | 53 (52.0%) | < 0.0001 |
| T2 | 83 (82.2%) | 18 (17.8%) | ||
| T3 | 103 (100.0%) | 0 (0.0%) | ||
| Exposure Risk | Non-high grade | 70 (74.5%) | 24 (25.5%) | 0.62 |
| High grade | 165 (77.8%) | 47 (22.2%) | ||
| COVID-19 Symptoms | No | 96 (75.0%) | 32 (25.0%) | 0.62 |
| Yes | 139 (78.1%) | 39 (21.9%) | ||
| Infection Category | Asymptomatic/ Mild | 211 (75.1%) | 70 (24.9%) | 0.034 |
| Moderate/Severe | 24 (96.0%) | 1 (4.0%) | ||
| Vaccinated | No | 99 (81.8%) | 22 (18.2%) | 0.12 |
| Yes | 156 (84,3%) | 19 (10,3%) |
Statistical inference was performed using Chi-squared test or Fisher test when needed.
COVID-19: Coronavirus Disease 2019; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2; IgG: Immunoglobulin G.